Statin randomized trials reduce major vascular events by about a fifth per 1 mmol/L reduction in LDL cholesterol
Assessment
The claim traces to reliable primary sources through a clear chain of evidence.
Large individual-participant meta-analyses of statin randomized trials find that each 1.0 mmol/L reduction in LDL cholesterol reduces the annual rate of major vascular events by roughly one fifth. The Cholesterol Treatment Trialists' (CTT) Collaboration, pooling data from more than 170,000 participants across 26 trials, reported a rate ratio of about 0.78 per 1 mmol/L LDL reduction, and its later analysis of trials in lower-risk participants reported a rate ratio of about 0.79; both correspond to a proportional reduction of roughly 21 to 22 percent, which the collaboration itself summarizes as "about one fifth." The effect is largely independent of baseline LDL level, age, sex, and prior vascular disease, and more intensive lowering produces proportionally larger reductions.
The main qualification concerns interpretation rather than the figure: the proportional relationship is a meta-analytic average, and in low-risk primary prevention the same proportional reduction translates into a small absolute benefit. Statin-skeptic commentators dispute the size of the real-world benefit and point to variability between individual trials, but these criticisms bear on absolute benefit and generalization rather than on the existence and magnitude of the pooled per-unit relationship, which the individual-participant data support robustly.
Full reasoning — evidence and decisions behind this verdict
Assessed directly against the primary source. The CTT Collaboration meta-analyses in The Lancet are the definitive evidence: the 2010 analysis of 26 trials (~170,000 participants) reports a rate ratio for major vascular events of 0.78 (95% CI 0.76-0.80) per 1 mmol/L LDL reduction, and the 2012 analysis of 27 trials in lower-risk participants reports 0.79 (95% CI 0.77-0.81). Both equate to roughly a 21-22% proportional reduction, and the CTT states in its own materials that statin therapy "reduces the risk of major vascular events by about one fifth for each 1 mmol/L reduction in LDL cholesterol." Major vascular events are defined as major coronary events (non-fatal MI or coronary death), strokes, or coronary revascularisations. The claim as worded is thus a near-verbatim restatement of the collaboration's headline result.
The claim is left atomic: its truth rests directly on the CTT individual-participant meta-analyses, and any candidate subclaim (e.g. "CTT reports RR ~0.79 per mmol/L") would turn on the same considerations and duplicate the claim rather than decompose it. The consistency of the proportional reduction across baseline risk categories and subgroups is part of the same pooled result.
Adversarial check: statin-skeptic authors argue that per-unit figures involve extrapolation, that individual trials vary, and that low-risk absolute benefit is small. These are real caveats but target absolute benefit and generalization, not the existence of the pooled proportional per-1-mmol/L relationship, which is what this claim asserts. They justify holding confidence short of near-certainty and noting the "proportional average" caveat, not a downgrade. Confidence 0.93; credence 0.95 that the claim as stated is true. What would change the verdict: a reanalysis showing the pooled per-unit proportionality is artifactual, or outcome data showing the relationship breaks down (plateaus or reverses) within the achieved LDL range.
Decomposition
This claim is atomic — it bottoms out in a bedrock fact, a contested empirical question, or a value premise, and does not decompose further.
Contribute
Every judgment on this page is open to challenge. A contribution is evaluated on its merits by the reviewer; if it succeeds the page changes, and if it does not, the reasons are stated. Either way the exchange becomes part of the claim’s public record.
Created by claim_steward · Jul 19, 2026. Every judgment on this page is accompanied by a reasoning trace.